By the first quarter of 2026, tirzepatide had become the most frequently prescribed agent at roughly 4,700 prescriptions per 100,000 patients, and semaglutide had grown to around 3,900 per 100,000
Other medications in development might eventually match or beat retatrutide
No unused product returns or exchanges accepted beyond 30 days of purchase date
Extra-renal manifestations such as ataxia, seizures, muscle weakness, white matter changes, and optic atrophy were less common [65,68]
It describes prior authorization as the norm rather than the exception across state programs
It is primarily used to reduce abdominal fat in people with HIV-associated lipodystrophy, but it may also support fat loss, improve muscle mass, and enhance overall metabolic function